Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood. - Wikidata - awgldk - TriplyDB

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.

http://www.wikidata.org/entity/Q33410392

about

Immune recruitment or suppression by glycan engineering of endogenous and therapeutic antibodies Biosimilar: what it is not Dimeric FcγR Ectodomains as Probes of the Fc Receptor Function of Anti-Influenza Virus IgG.Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma.Decreased levels of bisecting GlcNAc glycoforms of IgG are associated with human longevity.The N-Glycosylation of Mouse Immunoglobulin G (IgG)-Fragment Crystallizable Differs Between IgG Subclasses and Strains.Increased sialylation of anti-Thomsen-Friedenreich antigen (CD176) antibodies in patients with gastric cancer: a diagnostic and prognostic potential Novel data analysis tool for semiquantitative LC-MS-MS2 profiling of N-glycans.Macrophage and NK-mediated killing of precursor-B acute lymphoblastic leukemia cells targeted with a-fucosylated anti-CD19 humanized antibodies Clinical cancer therapy by NK cells via antibody-dependent cell-mediated cytotoxicity.The emerging importance of α-L-fucose in human breast cancer: a review.Analysis of carbohydrates and glycoconjugates by matrix-assisted laser desorption/ionization mass spectrometry: an update for 2009-2010.Mass spectrometric analysis of products of metabolic glycan engineering with azido-modification of sialic acids.Comparison of the Fc glycosylation of fetal and maternal immunoglobulin G Aberrant glycosylation of the anti-Thomsen-Friedenreich glycotope immunoglobulin G in gastric cancer patients.Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies.Glycosylation profile and biological activity of Remicade® compared with Flixabi® and Remsima®.Arabinosylation of recombinant human immunoglobulin-based protein therapeutics Reformatting Rituximab into Human IgG2 and IgG4 Isotypes Dramatically Improves Apoptosis Induction In Vitro.A global RNA-seq-driven analysis of CHO host and production cell lines reveals distinct differential expression patterns of genes contributing to recombinant antibody glycosylation.Drifts in ADCC-related quality attributes of Herceptin®: Impact on development of a trastuzumab biosimilar A novel anti-CD19 monoclonal antibody (GBR 401) with high killing activity against B cell malignancies.Uptake routes of tumor-antigen MAGE-A3 by dendritic cells determine priming of naïve T-cell subtypes.LC-MS analysis combined with principal component analysis and soft independent modelling by class analogy for a better detection of changes in N-glycosylation profiles of therapeutic glycoproteins.The novel complex combination of alum, CpG ODN and HH2 as adjuvant in cancer vaccine effectively suppresses tumor growth in vivo.Challenges with afucosylation content in antibody-based drugs: Guidance provided by mathematical modeling.Minimizing fucosylation in insect cell-derived glycoproteins reduces binding to IgE antibodies from the sera of patients with allergy Antitumor Efficacy of Anti-GD2 IgG1 Is Enhanced by Fc Glyco-Engineering Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.Production of non-fucosylated antibodies by co-expression of heterologous GDP-6-deoxy-D-lyxo-4-hexulose reductase.Crystallizable Fragment Glycoengineering for Therapeutic Antibodies Development.Modulation of IgG1 immunoeffector function by glycoengineering of the GDP-fucose biosynthesis pathway.Nanoscale reversed-phase liquid chromatography-mass spectrometry of permethylated N-glycans.MEDI-551 Treatment Effectively Depletes B Cells and Reduces Serum Titers of Autoantibodies in Mice Transgenic for Sle1 and Human CD19.

P2860

Q28069362-ED747211-CF6F-4026-8E02-C7EFAC84D610 Q28080880-3C433984-ACF6-4644-9B71-0E0D5FE7644C Q30390233-58E5ED53-F090-4806-B45B-150B0E6BF503 Q33621610-31B011CD-A8E2-4326-91F7-DD6789D370FE Q33689369-F0CA8483-B493-4957-8835-19A55A290ADC Q33740762-04FE2275-1706-40EF-A3E2-B433FD5F9BCD Q34208137-32E72075-A75F-4DA5-9683-E333AFDB7CCA Q34307304-941DC72A-4C40-44FF-AAED-CDB1FC4CD897 Q34598149-CD0D1B32-F999-434C-9721-D455341E31BB Q35031732-11AFCA37-9EF3-4E98-9DE1-1854BE83F801 Q35172546-68F3163C-FB8B-4DDB-A496-6E756DF8483A Q35174495-3CDFFAEC-D76C-4C75-84BF-F8F614F3482A Q35771248-DB73B039-A0D3-4C72-97EA-9054DCF8A6AA Q36554708-915D9D0B-9FD8-4881-98C0-D6077477665B Q36950893-EF300D08-C050-466A-A023-3D172193CC39 Q37364355-D00F3DC6-174B-4B03-9623-1943D194CC36 Q38699354-8ADE1173-0880-470F-901E-5AFB72F85858 Q38709004-2952EF00-1287-486B-BF26-88EB44B0B7E3 Q38808291-15B42605-D12D-48D2-B518-94F81264FFD3 Q38849069-E704DC11-2F85-40A2-AD4F-1C1B209FB5B0 Q38906179-854A90BC-D449-4B7C-B58C-A4FB58859E2E Q39004366-1DC0551C-F469-4719-9638-00D107227890 Q39352950-6970A215-C8B3-4EDB-A532-E1F36B201E9C Q39692794-9D21399B-2A8D-48C8-B4A2-3DC746699A52 Q41233846-0E181585-5F5D-4261-81AC-BBEBF3E739F1 Q41491243-460414D2-1CC1-4694-B6B3-798A266F4EA5 Q41825921-988264DC-7180-4501-9B94-D6EDECDE8B49 Q42415905-DBA0A702-42CA-4AAE-8CA6-F639F217143A Q42660142-7E22A673-7907-4DDF-A656-4D0FF9825F7F Q42966864-E3899FA9-745F-49E5-BAC8-1342217D1DFD Q44852748-93F5A787-EE75-463F-BFCA-8CADDC509382 Q48278134-76C03752-F7B9-4394-AA28-E3D86792E624 Q50497045-2DD56D8B-21B9-4A6D-8B6C-B58FB03EF785 Q53264199-5CB7ECAB-E576-4B29-AEAC-4AC2C33CF3D1

P2860

Two mechanisms of the enhanced antibody-dependent cellular cytotoxicity (ADCC) efficacy of non-fucosylated therapeutic antibodies in human blood.

http://www.wikidata.org/entity/Q33410392

description

2009 nî lūn-bûn

@nan

2009 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Two mechanisms of the enhanced ...... tic antibodies in human blood.

@ast

Two mechanisms of the enhanced ...... tic antibodies in human blood.

@en

type

label

Two mechanisms of the enhanced ...... tic antibodies in human blood.

@ast

Two mechanisms of the enhanced ...... tic antibodies in human blood.

@en

prefLabel

Two mechanisms of the enhanced ...... tic antibodies in human blood.

@ast

Two mechanisms of the enhanced ...... tic antibodies in human blood.

@en

P1433

Q33410392-CD9E8AC8-95E2-4EED-8A5E-6B7E5D34E94C

P1476

Q33410392-4EB70917-A277-4752-AF8F-44E109B894BA

P2093

Q33410392-2ED78B82-9E53-4279-9E3D-BC91B6B393C1

Q33410392-3602E7C1-674B-4E60-ABDC-9734203D68AF

Q33410392-74892806-4A05-4638-8137-8F2844E38046

Q33410392-B8E2C447-0966-46A2-B601-5B0B936B0549

Q33410392-CEA3462F-7048-4996-B31A-132C8547E255

Q33410392-DCD67451-A151-49FA-AE4F-1331CB6B7A41

Q33410392-EDE5E74F-9AB0-4AE9-BA97-1A62D0B3CEED

Q33410392-F781A240-3664-45B0-B9FE-5CF6879EFB32

P2860

Q33410392-0B250932-4140-450D-9521-48085CDFBFFC

Q33410392-1898E825-0165-4115-A2F6-331DBB41F779

Q33410392-3F35B5B3-0568-4FE8-B216-EE6A6DE2D36F

Q33410392-410A859E-189E-4DD8-B740-5A94C3B21E62

Q33410392-460119E7-E1CC-4A72-BF12-5EF56ADDED6B

Q33410392-4AA955B0-7969-4465-95A3-39E9B650BEFD

Q33410392-4BF942B1-A8F5-4315-90E3-C70C53E2ECC8

Q33410392-514CEF07-F476-48E6-B414-C46A69CEFBFE

Q33410392-5F1C8CD6-D9F6-4AA3-98F7-0524C0B1810F

Q33410392-6A7BF590-D6DA-4916-838A-F0B0194EE711

P2888

Q33410392-A04DCCEA-AA45-42C6-AA64-404E9F1EAAC3

P304

Q33410392-56CBFD74-D349-489D-A450-699DF2FC466C

P31

Q33410392-03B3EB49-31F9-419E-AD89-2BEB8D616079

P356

Q33410392-02B93735-4C69-44E6-AC32-54EB861C9F90

P407

Q33410392-BAFD3EAF-A697-49E3-A60D-985D17F2FF38

P478

Q33410392-A2B6A590-DC5C-4741-B439-8D118621F2C2

P577

Q33410392-6DC1CD68-7003-4754-9C47-03E8AA12DD34

P5875

Q33410392-9CEA02D2-16CF-4C7B-B168-2B1DCCB7F9A1

P6179

Q33410392-FCF094BF-C27C-4931-8A07-44CA092EB009

P698

Q33410392-B6E17FBC-D522-4B94-A2CA-7EEF6E82D346

P921

Q33410392-12859D41-1FDD-4CB1-B93E-12BB6FAEE199

Q33410392-6DCE7C86-0D19-47DF-819D-741D8AE54FEA

P932

Q33410392-526B02FF-1E86-4DE5-A68D-CE93CFC6EDE2

P356

P1433

P1476

Two mechanisms of the enhanced ...... tic antibodies in human blood.

@en

P2093

Akira Okazaki

http://www.w3.org/2001/XMLSchema#string

Hirofumi Misaka

http://www.w3.org/2001/XMLSchema#string

Katsuhiro Mori

http://www.w3.org/2001/XMLSchema#string

Kenya Shitara

http://www.w3.org/2001/XMLSchema#string

Miho Inoue

http://www.w3.org/2001/XMLSchema#string

Mitsuo Satoh

http://www.w3.org/2001/XMLSchema#string

Reiko Kuni-Kamochi

http://www.w3.org/2001/XMLSchema#string

Shigeru Iida

http://www.w3.org/2001/XMLSchema#string

P2860

Improving the efficacy of antibody-based cancer therapies

Structural studies on IgG oligosaccharides of patients with primary Sjögren's syndrome.

Profiling analysis of oligosaccharides in antibody pharmaceuticals by capillary electrophoresis.

Trastuzumab, a recombinant DNA-derived humanized monoclonal antibody, a novel agent for the treatment of metastatic breast cancer.

Mechanism of action of anti-HER2 monoclonal antibodies.

Establishment of FUT8 knockout Chinese hamster ovary cells: an ideal host cell line for producing completely defucosylated antibodies with enhanced antibody-dependent cellular cytotoxicity.

Engineered antibody Fc variants with enhanced effector function.

Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies.

The ErbB receptor family: a therapeutic target for cancer.

Renaissance of cancer therapeutic antibodies.

P2888

P304

58

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2407-9-58

http://www.w3.org/2001/XMLSchema#string

P407

P478

9

http://www.w3.org/2001/XMLSchema#string

P577

2009-02-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

24024392

http://www.w3.org/2001/XMLSchema#string

P6179

1020550079

http://www.w3.org/2001/XMLSchema#string

P698

19226457

http://www.w3.org/2001/XMLSchema#string

P921

P932

2649154

http://www.w3.org/2001/XMLSchema#string